• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis.

作者信息

Shalabi Doaa, Sethi Mansha, Okon Lauren, Debes Gudrun F, Lee Jason B, Nikbakht Neda

机构信息

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.

Department of Microbiology and Immunology, Sidney Kimmel Medical College and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

出版信息

JAAD Case Rep. 2019 Jul 31;5(8):663-665. doi: 10.1016/j.jdcr.2019.06.002. eCollection 2019 Aug.

DOI:10.1016/j.jdcr.2019.06.002
PMID:31388533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6677862/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f32b/6677862/6d94a34d303a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f32b/6677862/44470e58e3d1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f32b/6677862/adb3f339952b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f32b/6677862/6d94a34d303a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f32b/6677862/44470e58e3d1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f32b/6677862/adb3f339952b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f32b/6677862/6d94a34d303a/gr3.jpg

相似文献

1
Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis.α4β7整合素抑制剂维多珠单抗改善溃疡性结肠炎患者的淋巴浆细胞性黏膜炎。
JAAD Case Rep. 2019 Jul 31;5(8):663-665. doi: 10.1016/j.jdcr.2019.06.002. eCollection 2019 Aug.
2
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. vedolizumab 水平、抗药物抗体和 α4β7 占有率与炎症性肠病患者反应的相关性。
Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7. doi: 10.1016/j.cgh.2017.11.050. Epub 2017 Dec 7.
3
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab.溃疡性结肠炎黏膜炎症的程度影响维多珠单抗诱导的临床缓解。
J Clin Med. 2020 Feb 1;9(2):385. doi: 10.3390/jcm9020385.
4
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.维得利珠单抗：一种用于溃疡性结肠炎和克罗恩病的 α4β7 整合素拮抗剂。
Ther Adv Chronic Dis. 2015 Sep;6(5):224-33. doi: 10.1177/2040622315586970.
5
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.维多珠单抗治疗溃疡性结肠炎的药效学评估。
Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):833-42. doi: 10.1080/17425255.2016.1181171. Epub 2016 May 12.
6
Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.维多珠单抗：一种用于治疗炎症性肠病的α4β7整合素抑制剂。
Ann Pharmacother. 2014 Dec;48(12):1629-35. doi: 10.1177/1060028014549799. Epub 2014 Sep 3.
7
The safety of vedolizumab for the treatment of ulcerative colitis.维多珠单抗治疗溃疡性结肠炎的安全性。
Expert Opin Drug Saf. 2017 Apr;16(4):501-507. doi: 10.1080/14740338.2017.1300251. Epub 2017 Mar 5.
8
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.维多珠单抗：迈向溃疡性结肠炎患者个性化治疗模式
Clin Exp Gastroenterol. 2017 Mar 3;10:57-66. doi: 10.2147/CEG.S110547. eCollection 2017.
9
Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.识别与 vedolizumab 在炎症性肠病中的应答相关的候选生物标志物。
Dig Dis Sci. 2018 Sep;63(9):2419-2429. doi: 10.1007/s10620-018-4924-8. Epub 2018 Jan 25.
10
Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.比较 HIV 感染和溃疡性结肠炎中记忆 T 细胞亚群的整合素 α4β7 表达模式。
PLoS One. 2019 Jul 29;14(7):e0220008. doi: 10.1371/journal.pone.0220008. eCollection 2019.

本文引用的文献

1
Idiopathic lymphoplasmacellular mucositis of the lips: A case report and review of the literature.唇部特发性淋巴浆细胞性黏膜炎：一例报告并文献复习
J Cutan Pathol. 2017 Sep;44(9):776-780. doi: 10.1111/cup.12967. Epub 2017 Jun 23.
2
Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.维多珠单抗：一种用于治疗炎症性肠病的α4β7整合素抑制剂。
Ann Pharmacother. 2014 Dec;48(12):1629-35. doi: 10.1177/1060028014549799. Epub 2014 Sep 3.
3
Idiopathic lymphoplasmacellular mucositis-dermatitis of the eyelid.特发性眼睑淋巴浆细胞性黏膜炎-皮炎
Ophthalmic Plast Reconstr Surg. 2014 Nov-Dec;30(6):e149-51. doi: 10.1097/01.iop.0000440707.52043.87.
4
Consensus statement on the pathology of IgG4-related disease.关于 IgG4 相关疾病病理学的共识声明。
Mod Pathol. 2012 Sep;25(9):1181-92. doi: 10.1038/modpathol.2012.72. Epub 2012 May 18.
5
Idiopathic lymphoplasmacellular mucositis-dermatitis.特发性淋巴浆细胞性黏膜皮炎
J Cutan Pathol. 2010 Apr;37(4):426-31. doi: 10.1111/j.1600-0560.2009.01371.x. Epub 2009 Jul 15.
6
Plasma cell mucositis of the oral cavity: report of a case and review of the literature.口腔浆细胞性黏膜炎：一例报告及文献复习
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Dec;106(6):853-60. doi: 10.1016/j.tripleo.2008.08.016. Epub 2008 Oct 16.
7
[Chronic benign circumscript plasmocytic balanoposthitis].[慢性良性局限性浆细胞性龟头炎]
Dermatologica. 1952;105(1):1-7.
8
Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses.全身、肠道和鼻腔免疫后人类循环抗体形成细胞上组织特异性黏附分子的差异表达。效应B细胞反应分区化的分子基础。
J Clin Invest. 1997 Mar 15;99(6):1281-6. doi: 10.1172/JCI119286.
9
Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.α4β7整合素介导淋巴细胞与黏膜血管地址素MAdCAM-1的结合。
Cell. 1993 Jul 16;74(1):185-95. doi: 10.1016/0092-8674(93)90305-a.